ESR1 and breast cancer: Moreover, our calculated risks are similar to those reported in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database, that is, a contralateral breast cancer risk of approximately 2.5% to 12.6% in 10 years depending on estrogen receptor status and age at onset [18,19].